Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developments in hepatitis C therapy during 2000-2002.

F Fred Poordad1, Tram Tran, Paul Martin

  • 1Department of Hepatology and Liver Transplantation, Cedars-Sinai Medical Center, 8635 W. Third St, #590W, Los Angeles, CA 90048, USA.

Expert Opinion on Emerging Drugs
|November 13, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing.

Blood advances·2020
Same author

Reversible methamphetamine-induced cardiomyopathy mimicking arrhythmogenic right ventricular cardiomyopathy with ventricular tachycardia.

HeartRhythm case reports·2020
Same author

Outcomes After Direct-Acting Antiviral Therapy Based on Donor Hepatitis C Serostatus Among Hepatitis C Virus-Infected Kidney Transplant Recipients.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation·2020
Same author

Novel targeted therapies for the management of liver fibrosis.

Expert opinion on emerging drugs·2020
Same author

The authors reply.

Kidney international·2020
Same author

Introducing the CME/MOC Corner.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2019

Hepatitis C virus (HCV) infection affects millions globally and is a leading cause of liver disease. This review examines patent literature from 2000-2002 for potential Hepatitis C virus treatments.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis C virus (HCV) affects 170 million people worldwide, causing significant liver disease.
  • HCV is the primary reason for liver transplantation in the United States.
  • Most individuals with HCV are candidates for treatment.

Purpose of the Study:

  • To review patent literature concerning Hepatitis C virus (HCV) treatment modalities from 2000 to mid-2002.
  • To discuss the potential of various therapeutic approaches for HCV based on patent filings.

Main Methods:

  • Literature review of patent filings.
  • Analysis of therapeutic strategies for Hepatitis C virus (HCV).

Main Results:

  • The patent literature from 2000-2002 reveals diverse approaches to Hepatitis C virus (HCV) treatment.

Related Experiment Videos

  • Several potential therapeutic modalities were explored during this period.

    • Conclusions:

    • The period 2000-mid-2002 saw significant innovation in Hepatitis C virus (HCV) treatment research, as reflected in patent filings.
    • Further development of these patented strategies holds promise for managing Hepatitis C virus (HCV) infection.